Barclays Q4 Preview: Kimberly-Clark (KMB) Target Cut, “enthusiasm” Not Driven by Fundamentals

Group 1 - Barclays has cut its price target for Kimberly-Clark Corporation (KMB) from $132 to $102 while maintaining an Equal Weight rating, indicating a cautious outlook for the stock [2] - The recent enthusiasm for Kimberly-Clark shares is attributed to a "flight to safety" rather than improvements in the company's fundamentals, with concerns about company-specific and sector conditions persisting [3] - Institutional Shareholder Services (ISS) has recommended that Kimberly-Clark shareholders support the proposed acquisition of Kenvue, suggesting it could enhance the company's financial profile and key metrics [4][5] Group 2 - The proposed acquisition of Kenvue, valued at over $40 billion, aims to create a global consumer health platform that combines well-known brands from both companies [6] - ISS acknowledges potential shareholder concerns regarding the market's negative reaction to the acquisition announcement and uncertainties related to litigation involving Kenvue products, but believes the merger could unlock significant synergies [7] - Kimberly-Clark is recognized as a global consumer products company focused on improving care and hygiene through a range of essential products [8]